Cresemba (isavuconazonium sulfate) capsules — Highmark
invasive mucormycosis
Initial criteria
- age ≥ 6 years
- If pediatric, weight ≥ 16 kg
- Diagnosis of mucormycosis infection (ICD-10: B46.5), classified as invasive
Reauthorization criteria
- Prescriber attests to the presence of continued indicators of active disease (e.g., histopathology, fungal culture)
Approval duration
3 months